Development of an in vitro assay using abscisic acid to study Toxoplasma gondii infectivity.

Exp Parasitol

Institute of Parasitology, Faculty of Veterinary Medicine, Leipzig University, Leipzig, Germany; Tifton Veterinary Diagnostic and Investigational Laboratory and Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Tifton, USA. Electronic address: berit.bangoura@u

Published: September 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The common parasite Toxoplasma gondii can infect all warm-blooded animals, including humans. Although most infections in humans remain asymptomatic, clinical toxoplasmosis can develop into a fatal disease. Infections are usually contracted by oral ingestion of tissue cysts or oocysts contained in cat feces. Currently, the mouse bioassay is applied as a final experiment to evaluate meat infectivity. This study aims to establish an alternative cell culture and quantitative polymerase chain reaction (qPCR)-based in vitro infectivity assay for tissue cysts. The phytohormone abscisic acid (ABA) is applied to increase parasite multiplication. A human foreskin fibroblast (HFF) host cell culture was infected with bradyzoites from mouse tissue. Treatment groups included uninfected controls, infected untreated controls, and infected ABA treated groups. The applied ABA concentrations used ranged from 0.2 ng/μl to 20 ng/μl, and ABA incubation times ranged from 2 h to 18 h before ABA removal. At 48 h after infection, T. gondii deoxyribonucleic acid (DNA) in the cell cultures was quantified by qPCR. The results indicate that parasite DNA copy numbers are markedly increased when using ABA at 2 ng/μl for 4 - 6 h or at 20 ng/μl for 2 h incubation. Our results indicate that this newly established in vitro assay is suitable to determine T. gondii cyst infectivity.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exppara.2025.109011DOI Listing

Publication Analysis

Top Keywords

vitro assay
8
abscisic acid
8
toxoplasma gondii
8
tissue cysts
8
cell culture
8
controls infected
8
ng/μl ng/μl
8
aba
6
development vitro
4
assay abscisic
4

Similar Publications

Aims: The increasing antimicrobial resistance, particularly in Acinetobacter baumannii, complicates the treatment of infections, leading to higher morbidity, mortality, and economic costs. Herein, we aimed to determine the in vitro antimicrobial, synergistic, and antibiofilm activities of colistin (COL), meropenem, and ciprofloxacin antibiotics, and curcumin, punicalagin, geraniol (GER), and linalool (LIN) plant-active ingredients alone and in combination against 31 multidrug-resistant (MDR) A. baumannii clinical isolates.

View Article and Find Full Text PDF

Objectives: Acute lung injury (ALI) is an acute respiratory failure syndrome characterized by impaired gas exchange. Due to the lack of effective targeted drugs, it is associated with high mortality and poor prognosis. (TW) has demonstrated anti-inflammatory activity in the treatment of various diseases.

View Article and Find Full Text PDF

Donor-derived cell-free DNA (dd-cfDNA) has emerged as a valuable noninvasive biomarker for detecting allograft injury in solid organ transplantation. It is released into the bloodstream from the transplanted organ as a result of cell injury and immune activation, with baseline levels influenced by organ type, tissue turnover, and posttransplant physiological changes. Several analytical platforms are available, including quantitative polymerase chain reaction (PCR), digital droplet PCR, and next-generation sequencing, each differing in sensitivity, throughput, and reporting format.

View Article and Find Full Text PDF

Esophageal cancer is a major cause of cancer-related death, often preceded with chronic inflammation and injuries. The NFκB/IKKβ pathway plays a central role in inflammation, yet its role in early esophageal carcinogenesis remains unclear. This study investigated the role of epithelial IKKβ in early esophageal carcinogenesis.

View Article and Find Full Text PDF

Avapritinib (Ayvakit™) is a highly selective inhibitor of the platelet-derived growth factor receptor alpha (PDGFRA), including D842V mutations. Avapritinib (APB) is authorized in the United States for individuals with metastatic or unresectable gastrointestinal stromal tumors (GISTs). APB is considered the exclusive therapy for adults with indolent systemic mastocytosis.

View Article and Find Full Text PDF